The place of immunotherapy in the management of HCV-induced vasculitis: An update

Clinical and Developmental Immunology

Volumn 2012, Issue , 2012, Pages

  Chiche, Laurent ^a   Bataille, Stanislas ^b   Kaplanski, Gilles ^a   Jourde, Noemie ^b  

^a HÔPITAL DE LA CONCEPTION   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BOCEPREVIR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; PEGINTERFERON ALPHA; RECOMBINANT INTERLEUKIN 2; RIBAVIRIN; RITUXIMAB; TELAPREVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; HEPATITIS C ANTIBODY; INTERLEUKIN 2; MACROGOL DERIVATIVE; MONOCLONAL ANTIBODY; PEGINTERFERON ALPHA2A; RECOMBINANT PROTEIN;

ANTIVIRAL THERAPY; CORTICOSTEROID THERAPY; HEPATITIS C; HEPATITIS C VIRUS INDUCED CRYOGLOBULINEMIC VASCULITIS; HUMAN; IMMUNOTHERAPY; NONHUMAN; PLASMAPHERESIS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; VASCULITIS; VIRUS LOAD; HEPATITIS C VIRUS; IMMUNOLOGY; PATHOGENICITY; VIROLOGY;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIVIRAL AGENTS; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; IMMUNOTHERAPY; INTERFERON-ALPHA; INTERLEUKIN-2; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; VASCULITIS;

EID: 84866166045     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2012/315167     Document Type: Review

References (53)

1. Landau D. A., Scerra S., Sene D., Resche-Rigon M., Saadoun D., Cacoub P., Causes and predictive factors of mortality in a cohort of patients with hepatitis C virus-related cryoglobulinemic vasculitis treated with antiviral therapy. Journal of Rheumatology 2010 37 3 615 621 2-s2.0-77949696600 10.3899/jrheum.090790
2. Manns M. P., McHutchison J. G., Gordon S. C., Rustgi V. K., Shiffman M., Reindollar R., Goodman Z. D., Koury K., Ling M. H., Albrecht J. K., Peginterferon alfa-2b plus ribavirin compared with interferonalfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. The Lancet 2001 358 9286 958 965 2-s2.0-0035934568 10.1016/S0140-6736(01)06102-5 (Pubitemid 32913521)
3. Fried M. W., Shiffman M. L., Rajender Reddy K., Smith C., Marinos G., Goncales J. F. L., Häussinger D., Diago M., Carosi G., Dhumeaux D., Craxi A., Lin A., Hoffman J., Yu J., Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New England Journal of Medicine 2002 347 13 975 982 2-s2.0-0037179698 10.1056/NEJMoa020047
4. Hadziyannis S. J., Sette H., Morgan T. R., Balan V., Diago M., Marcellin P., Ramadori G., Bodenheimer H., Bernstein D., Rizzetto M., Zeuzem S., Pockros P. J., Lin A., Ackrill A. M., Peginterferon- α 2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Annals of Internal Medicine 2004 140 5 346 I67 2-s2.0-1542378867
5. Cavallo R., Roccatello D., Menegatti E., Naretto C., Napoli F., Baldovino S., Rituximab in cryoglobulinemic peripheral neuropathy. Journal of Neurology 2009 256 7 1076 1082 2-s2.0-67650463116 10.1007/s00415-009-5072-z
6. Petrarca A., Rigacci L., Caini P., Colagrande S., Romagnoli P., Vizzutti F., Arena U., Giannini C., Monti M., Montalto P., Matucci-Cerinic M., Bosi A., Laffi G., Zignego A. L., Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease. Blood 2010 116 3 335 342 2-s2.0-77955915180 10.1182/blood-2009-11-253948
7. Batisse D., Karmochkine M., Jacquot C., Kazatchkine M. D., Weiss L., Sustained exacerbation of cryoglobulinaemia-related vasculitis following treatment of hepatitis C with peginterferon alfa. European Journal of Gastroenterology and Hepatology 2004 16 7 701 703 2-s2.0-3142550646 10.1097/01.meg.0000108342.41221.0c (Pubitemid 38901640)
8. Lidove O., Cacoub P., Hausfater P., Wechsler B., Frances C., Leger J. M., Piette J. C., Hepatits C virus and cryoglobulinemia: worsening of peripheral neuropathy after interferon alpha treatment. Gastroenterologie Clinique et Biologique 1999 23 3 403 406 2-s2.0-0033094204 (Pubitemid 29262429)
9. Mazzaro C., Zorat F., Caizzi M., Donada C., Di Gennaro G., Dal Maso L., Carniello G., Virgolini L., Tirelli U., Pozzato G., Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study. Journal of Hepatology 2005 42 5 632 638 2-s2.0-20144387752 10.1016/j.jhep.2004.10.031
10. Cacoub P., Saadoun D., Limal N., Sene D., Lidove O., Piette J. C., PEGylated interferon Alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis and Rheumatism 2005 52 3 911 915 2-s2.0-14944373284 10.1002/art.20958 (Pubitemid 40365115)
11. Ghany M. G., Nelson D. R., Strader D. B., Thomas D. L., Seeff L. B., An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011 54 4 1433 1444 10.1002/hep.24641
12. Pietrogrande M., De Vita S., Zignego A. L., Pioltelli P., Sansonno D., Sollima S., Atzeni F., Saccardo F., Quartuccio L., Bruno S., Bruno R., Campanini M., Candela M., Castelnovo L., Gabrielli A., Gaeta G. B., Marson P., Mascia M. T., Mazzaro C., Mazzotta F., Meroni P., Montecucco C., Ossi E., Piccinino F., Prati D., Puoti M., Riboldi P., Riva A., Roccatello D., Sagnelli E., Scaini P., Scarpato S., Sinico R., Taliani G., Tavoni A., Bonacci E., Renoldi P., Filippini D., Sarzi-Puttini P., Ferri C., Monti G., Galli M., Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. Autoimmunity Reviews 2011 10 8 444 454 2-s2.0-79957655345 10.1016/j.autrev.2011.01.008
13. Bini E. J., Mehandru S., Incidence of thyroid dysfunction during interferon alfa-2b and ribavirin therapy in men with chronic hepatitis C: a prospective cohort study. Archives of Internal Medicine 2004 164 21 2371 2376 2-s2.0-8844247779 10.1001/archinte.164.21.2371 (Pubitemid 39532250)
14. Almeida A. G. D., Guindalini C., Batista-Neves S., de Oliveira I. R., Miranda-Scippa A., Quarantini L. C., Can antidepressants prevent interferon-alpha-induced depression? A review of the literature. General Hospital Psychiatry 2010 32 4 401 405 2-s2.0-77954620563 10.1016/j.genhosppsych. 2010.03.001
15. Rasul I., Shepherd F. A., Kamel-Reid S., Krajden M., Pantalony D., Jenny Heathcote E., Detection of occult low-grade B-cell non-Hodgkin's lymphoma in patients with chronic hepatitis C infection and mixed cryoglobulinemia. Hepatology 1999 29 2 543 547 2-s2.0-0033018256 10.1002/hep.510290224 (Pubitemid 29088460)
16. Landau D. A., Saadoun D., Halfon P., Martinot-Peignoux M., Marcellin P., Fois E., Cacoub P., Relapse of hepatitis C virus-associated mixed cryoglobulinemia vasculitis in patients with sustained viral response. Arthritis and Rheumatism 2008 58 2 604 611 2-s2.0-39749085148 10.1002/art.23305 (Pubitemid 351294898)
17. Casato M., Lilli D., Donato G., Granata M., Conti V., Del Giudice G., Rivanera D., Scagnolari C., Antonelli G., Fiorilli M., Occult hepatitis C virus infection in type II mixed cryoglobulinaemia. Journal of Viral Hepatitis 2003 10 6 455 459 2-s2.0-10744233891 10.1046/j.1365-2893.2003.00462.x (Pubitemid 37352588)
18. Zaghloul H., El-Sherbiny W., Detection of occult hepatitis C and hepatitis B virus infections from peripheral blood mononuclear cells. Immunological Investigations 2010 39 3 284 291 2-s2.0-77950786706 10.3109/08820131003605820
19. Welker M. W., Zeuzem S., Occult hepatitis C: how convincing are the current data? Hepatology 2009 49 2 665 675 2-s2.0-61949417110 10.1002/hep.22706
20. Bataille S., Kaplanski G., Boucraut J., Halfon P., Camus C., Daniel L., Burtey S., Berland Y., Dussol B., Membranoproliferative glomerulonephritis and mixed cryoglobulinemia after hepatitis C virus infection secondary to glomerular NS3 viral antigen deposits. American Journal of Nephrology 2012 35 2 134 140 10.1159/000335375
21. Halfon P., Bourlière M., Ouzan D., Sène D., Saadoun D., Khiri H., Pénaranda G., Martineau A., Oulès V., Cacoub P., Occult hepatitis C virus infection revisited with ultrasensitive real-time PCR assay. Journal of Clinical Microbiology 2008 46 6 2106 2108 2-s2.0-45149086647 10.1128/JCM.00345-08 (Pubitemid 351831855)
22. Terrier B., Krastinova E., Marie I., Management of non-infectious mixed cryoglobulinemia vasculitis: data from 242 cases included in the CryoVas survey. Blood 2012 119 25 5996 6004 10.1182/blood-2011-12-396028
23. Chandesris M. O., Gayet S., Schleinitz N., Doudier B., Harlé J. R., Kaplanski G., Infliximab in the treatment of refractory vasculitis secondary to heptitis C-associated mixed cryoglobulinaemia [9]. Rheumatology 2004 43 4 532 533 2-s2.0-1842866197 10.1093/rheumatology/keh080 (Pubitemid 38489381)
24. Bartolucci P., Ramanoelina J., Cohen P., Mahr A., Godmer P., Le Hello C., Guillevin L., Efficacy of the anti-TNF- α antibody infliximab against refractory systemic vasculitidis: an open pilot study on 10 patients. Rheumatology 2002 41 10 1126 1132 2-s2.0-0036796830 (Pubitemid 35203539)
25. Josselin L., Mahr A., Cohen P., Pagnoux C., Guaydier-Souquières G., Hayem G., Job-Deslandre C., Liferman F., Pourrat J., Guillevin L., Infliximab efficacy and safety against refractory systemic necrotising vasculitides: long-term follow-up of 15 patients. Annals of the Rheumatic Diseases 2008 67 9 1343 1346 2-s2.0-50249179755 10.1136/ard.2007.083584
26. Cohen C., Mekinian A., Saidenberg-Kermanac'h N., Stirnemann J., Fenaux P., Gherardi R., Fain O., Efficacy of tocilizumab in rituximab-refractory cryoglobulinemia vasculitis. Annals of the Rheumatic Diseases 2012 71 4 628 629 10.1136/annrheumdis-2011-200501
27. Saadoun D., Rosenzwajg M., Joly F., Six A., Carrat F., Thibault V., Sene D., Cacoub P., Klatzmann D., Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. New England Journal of Medicine 2011 365 22 2067 2077
28. Sansonno D., Carbone A., De Re V., Dammacco F., Hepatitis C virus infection, cryoglobulinaemia, and beyond. Rheumatology 2007 46 4 572 578 2-s2.0-34047118683 10.1093/rheumatology/kel425 (Pubitemid 46523298)
29. Sansonno D., De Re V., Lauletta G., Tucci F. A., Boiocchi M., Dammacco F., Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon α with an anti-CD20. Blood 2003 101 10 3818 3826 2-s2.0-0038603204 10.1182/blood-2002-10-3162 (Pubitemid 36857852)
30. Zaja F., De Vita S., Mazzaro C., Sacco S., Damiani D., De Marchi G., Michelutti A., Baccarani M., Fanin R., Ferraccioli G., Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003 101 10 3827 3834 2-s2.0-0037926826 10.1182/blood-2002-09-2856 (Pubitemid 36857853)
31. Quartuccio L., Soardo G., Romano G., Zaja F., Scott C. A., De Marchi G., Fabris M., Ferraccioli G., De Vita S., Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids. Rheumatology 2006 45 7 842 846 2-s2.0-33745631505 10.1093/rheumatology/kel004 (Pubitemid 43985372)
32. Dammacco F., Tucci F. A., Lauletta G., Gatti P., De Re V., Conteduca V., Sansonno S., Russi S., Mariggiò M. A., Chironna M., Sansonno D., Pegylated interferon- α ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study. Blood 2010 116 3 343 353 2-s2.0-77954869956 10.1182/blood-2009-10-245878
33. Saadoun D., Rigon M. R., Sene D., Terrier B., Karras A., Perard L., Schoindre Y., Coppéré B., Blanc F., Musset L., Piette J. C., Rosenzwajg M., Cacoub P., Rituximab plus Peg-interferon- α /ribavirin compared with Peg-interferon- α /ribavirin in hepatitis C-related mixed cryoglobulinemia. Blood 2010 116 3 326 334 2-s2.0-77955857269 10.1182/blood-2009-10-248518
34. De Vita S., Quartuccio L., Isola M., Mazzaro C., Scaini P., Lenzi M., Campanini M., Naclerio C., Tavoni A., Pietrogrande M., Ferri C., Mascia M. T., Masolini P., Zabotti A., Maset M., Roccatello D., Zignego A. L., Pioltelli P., Gabrielli A., Filippini D., Perrella O., Migliaresi S., Galli M., Bombardieri S., Monti G., A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis and Rheumatism 2012 64 3 843 853 10.1002/art.34331
35. Sneller M. C., Hu Z., Langford C. A., A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. Arthritis and Rheumatism 2012 64 3 835 842 10.1002/art.34322
36. Ferri C., Cacoub P., Mazzaro C., Roccatello D., Scaini P., Sebastiani M., Tavoni A., Zignego A. L., De Vita S., Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature. Autoimmunity Reviews 2011 11 1 48 55 10.1016/j.autrev.2011. 07.005
37. Cacoub P., Delluc A., Saadoun D., Landau D. A., Sene D., Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemia vasculitis: where do we stand? Annals of the Rheumatic Diseases 2008 67 3 283 287 2-s2.0-39549109812 10.1136/ard.2006.065565 (Pubitemid 351281259)
38. Brah S., Chiche L., Fanciullino R., Bornet C., Mancini J., Schleinitz N., Jean R., Kaplanski G., Harlé J. R., Durand J. M., Efficacy of rituximab in immune thrombocytopenic purpura: a retrospective survey. Annals of Hematology 2011 1 7 2-s2.0-79959409896 10.1007/s00277-011-1283-3
39. Sène D., Ghillani-Dalbin P., Amoura Z., Musset L., Cacoub P., Rituximab may form a complex with IgM κ mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis. Arthritis and Rheumatism 2009 60 12 3848 3855 2-s2.0-73249120052 10.1002/art.25000
40. Terrier B., Saadoun D., Sène D., Sellam J., Pérard L., Coppéré B., Karras A., Blanc F., Buchler M., Plaisier E., Ghillani P., Rosenzwajg M., Cacoub P., Efficacy and tolerability of rituximab with or without PEGylated interferon alfa-2b plus ribavirin in severe hepatitis C virus-related vasculitis: a long-term followup study of thirty-two patients. Arthritis and Rheumatism 2009 60 8 2531 2540 2-s2.0-68049110509 10.1002/art.24703
41. Terrier B., Launay D., Kaplanski G., Hot A., Larroche C., Cathébras P., Combe B., de Jaureguiberry J. P., Meyer O., Schaeverbeke T., Somogyi A., Tricot L., Zénone T., Ravaud P., Gottenberg J. E., Mariette X., Cacoub P., Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: data from the French Autoimmunity and Rituximab registry. Arthritis Care & Research 2010 62 12 1787 1795 2-s2.0-79952115984
42. van Assen S., Elkayam O., Agmon-Levin N., Cervera R., Doran M. F., Dougados M., Emery P., Geborek P., Ioannidis J. P. A., Jayne D. R. W., Kallenberg C. G. M., Müller-Ladner U., Shoenfeld Y., Stojanovich L., Valesini G., Wulffraat N. M., Bijl M., Vaccination in adult patients with auto-immune inflammatory rheumatic diseases: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for vaccination in adult patients with auto-immune inflammatory rheumatic diseases. Autoimmunity Reviews 2011 10 6 341 352 2-s2.0-79953161956 10.1016/j.autrev.2010. 12.003
43. Koreth J., Matsuoka K.-I., Kim H. T., McDonough S. M., Bindra B., Alyea E. P. III, Armand P., Cutler C., Ho V. T., Treister N. S., Bienfang D. C., Prasad S., Tzachanis D., Joyce R. M., Avigan D. E., Antin J. H., Ritz J., Soiffer R. J., Interleukin-2 and regulatory T cells in graft-versus-host disease. New England Journal of Medicine 2011 365 22 2055 2066
44. Antony G. K., Dudek A. Z., Interleukin 2 in cancer therapy. Current Medicinal Chemistry 2010 17 29 3297 3302 2-s2.0-77957936264
45. 4+ T-cell counts following antiretroviral cessation in patients with HIV. AIDS 2012 26 6 711 720 10.1097/QAD.0b013e3283519214
46. Bluestone J. A., Auchincloss H., Nepom G. T., Rotrosen D., Clair S., Turka L. A., The immune tolerance network at 10 years: tolerance research at the bedside. Nature Reviews Immunology 2010 10 11 797 803 2-s2.0-77958604019 10.1038/nri2869
47. Landau D. A., Rosenzwajg M., Saadoun D., Trébeden-Negre H., Klatzmann D., Cacoub P., Correlation of clinical and virologic responses to antiviral treatment and regulatory T cell evolution in patients with hepatitis C virus-induced mixed cryoglobulinemia vasculitis. Arthritis and Rheumatism 2008 58 9 2897 2907 2-s2.0-51849115547 10.1002/art.23759
48. Veerapathran A., Pidala J., Beato F., Yu X.-Z., Anasetti C., Ex vivo expansion of human Tregs specific for alloantigens presented directly or indirectly. Blood 2011 118 20 5671 5680 10.1182/blood-2011-02-337097
49. Grinberg-Bleyer Y., Baeyens A., You S., Elhage R., Fourcade G., Gregoire S., Cagnard N., Carpentier W., Tang Q., Bluestone J., Chatenoud L., Klatzmann D., Salomon B. L., Piaggio E., IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. Journal of Experimental Medicine 2010 207 9 1871 1878 2-s2.0-77956257716 10.1084/jem.20100209
50. Long S. A., Rapamycin plus IL 2 combination therapy in subjects with T1D results in a sustained increase in IL 2 responsiveness and a transient decrease in C-peptide levels. Proceedings of the 71st Scientific Sessions American Diabetes Association Annual Meeting June 2011 San Diego, Calif, USA 24 28
51. Webster K. E., Walters S., Kohler R. E., Mrkvan T., Boyman O., Surh C. D., Grey S. T., Sprent J., In vivo expansion of t reg cells with il-2-mab complexes: induction of resistance to eae and long-term acceptance of islet allografts without immunosuppression. Journal of Experimental Medicine 2009 206 4 751 760 2-s2.0-65549091509 10.1084/jem.20082824
52. Quartuccio L., Soardo G., Romano G., Zaja F., Scott C. A., De Marchi G., Fabris M., Ferraccioli G., De Vita S., Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids. Rheumatology 2006 45 7 842 846 2-s2.0-33745631505 10.1093/rheumatology/kel004 (Pubitemid 43985372)
53. Visentini M., Ludovisi S., Petrarca A., Pulvirenti F., Zaramella M., Monti M., Conti V., Ranieri J., Colantuono S., Fognani E., Piluso A., Tinelli C., Zignego A. L., Mondelli M. U., Fiorilli M., Casato M., A phase II, single-arm multicenter study of low-dose rituximab for refractory mixed cryoglobulinemia secondary to hepatitis C virus infection. Autoimmunity Reviews 2011 2-s2.0-79955944847 10.1016/j.autrev.2011.04.033